Conflict of interest The authors of this manuscript have the following competing interests: RN has received honoraria from Sanofi Co., Ltd., Japan Medtronic Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Teijin, Kissei Pharmaceutical Co., Ltd., Abbott, Eli Lilly Japan Co., Ltd., Novo Nordisk Pharma Co., Ltd., and Astellas Pharma Inc
I'm grateful that I live at a time when the biology and pathophysiology of obesity are understood, and we have a treatment that is safe and effective
Separating medication-caused pancreatitis from coincidental pancreatitis in a high-risk population remains methodologically challenging
The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention, said Fatima Cody Stanford, MD, associate professor of medicine and pediatrics at Harvard Medical School, who was not involved in the study